Eiger Bio’s Apelian Gives Notice, Takes CEO Job at Private Biotech

Posted by |2019-05-20T03:30:07-07:00May 17th, 2019|

David Apelian, chief operating officer and executive medical officer at Eiger BioPharmaceuticals (NASDAQ: EIGR) for the past 17 months, is stepping down. The Palo Alto, CA, drug developer said Friday that Apelian accepted an offer to become CEO of an unnamed private biotech company. Apelian, whose last day will be June 14, will remain on […]

ASCO Abstracts: Breast Cancer, Precision Treatments in the Spotlight

Posted by |2019-05-16T10:09:43-07:00May 16th, 2019|

The world’s biggest annual cancer conference is just around the corner. Data presented at the American Society of Clinical Oncology meeting each year can change medical practice and make or break companies whose drugs are under the microscope. That’s what makes even the “abstracts,” or snippets of data revealed a few weeks before the meeting, […]

Whiskey Coffee, Immigration, AI: MassChallenge Austin 2019 Startups

Posted by |2019-05-15T15:48:14-07:00May 15th, 2019|

Austin—MassChallenge has picked the 74 early-stage companies that will eventually compete for a portion of $500,000 in cash as a part of its Austin accelerator program. They’re startups that are developing products in a wide range of sectors, including life sciences, agriculture, and artificial intelligence. A majority of the startups are from Texas, although some […]

Klickstein Leaves NIBR for resTORbio Chief Scientific Officer Role

Posted by |2019-05-14T07:40:45-07:00May 14th, 2019|

Lloyd Klickstein has joined resTORbio (NASDAQ: TORC) as chief scientific officer. Klickstein comes to Boston-based resTORbio from the Novartis Institutes for Biomedical Research (NIBR), where was global head of translational medicine for the new indication discovery unit and the exploratory disease area. Last year, resTORbio reported positive data for lead drug RTB101, which was developed […]

Meet the X of the Year Finalists for the Xconomy Awards San Diego

Posted by |2019-05-13T07:00:27-07:00May 13th, 2019|

The Xconomy Awards categories weren’t enough to capture the full diversity of the San Diego life science community. So we at Xconomy created X of the Year for people who are so unique they needed their own categories. Read on for short introductions of the X of the Year finalists. This is part of a […]

Register Today and Save on “What’s Hot in Boston Biotech” on May 21

Posted by |2019-05-13T03:30:07-07:00May 10th, 2019|

It finally is starting to feel like spring in Boston, which means our annual half-day life science forum, “What’s Hot in Boston Biotech,” is just around the corner. It’s happening on Tuesday, May 21, at Bristol-Myers Squibb in Cambridge, MA. We’re convening an elite and eclectic group of life sciences executives, researchers, and investors from […]

Two Days, Five Biotech IPOs, and $359M Raised for Clinical Trials

Posted by |2019-05-09T05:23:42-07:00May 9th, 2019|

It will be hard to top last year’s flurry of biotech companies joining the public markets, but this week is shaping up to be the busiest for life science IPOs in recent memory. Five biotechs priced their IPOs and at least one more is coming. According to IPO research firm Renaissance Capital, 47 IPOs have […]

Super Saver Rate for Seattle Life Science Xchange Event Ends Tomorrow

Posted by |2019-05-08T04:00:48-07:00May 8th, 2019|

Grab your ticket now to attend Life Science Xchange: Closer to Convergence. Join Xconomy on June 25 at Cambia Grove in Seattle to hear the stories of local organizations taking advantage of the growing convergence of biology and data to discover, develop, and deliver healthcare innovation to patients— in the form of drugs, diagnostics, devices, […]

SMA, Migraine Data Lead Neuro Highlights from AAN Meeting

Posted by |2019-05-07T13:10:26-07:00May 7th, 2019|

The American Academy of Neurology meeting in Philadelphia is rolling on through the end of this week. There has been plenty of news to digest already. New clinical data could herald cutting-edge treatments for migraine, the rare disease spinal muscular atrophy, the deadly neurological disorder amyotrophic lateral sclerosis, and more. Xconomy previewed the conference last […]

Verve Has Top Cardio-Geneticist, $58.5M to Aim CRISPR at Heart Attacks

Posted by |2019-05-07T01:55:29-07:00May 7th, 2019|

A new startup wants to edit out the world’s biggest killer. Prominent cardiologist and geneticist Sekar Kathiresan is heading up a new company, Verve Therapeutics, that will develop gene-altering medicine to prevent heart attacks. Heart disease is the leading cause of death in the US and worldwide. “Imagine an injection, once in life, that safely […]

Bellicum Pharma’s Grossman Joins Arcus Bio as Chief Medical Officer

Posted by |2019-05-06T03:30:06-07:00May 3rd, 2019|

William Grossman has joined Arcus Biosciences (NYSE: RCUS) as chief medical officer, the same position he held at his former company, Bellicum Pharmaceuticals (NASDAQ: BLCM). Grossman’s experience also includes positions at Genentech, AbbVie (NYSE: ABBV), and Biothera. Hayward, CA-based Arcus, which raised $120 million in its IPO last year, has several cancer drugs in early-stage […]

At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments

Posted by |2019-05-03T02:00:20-07:00May 3rd, 2019|

The first new class of migraine drugs in decades won FDA approval last year. But the companies who commercialized these new therapies and their potential competitors are already planning new, more convenient versions, taken as pills instead of injectoins just below the skin, and they will present key data in the next few days at […]

Load More Posts